Fusion Antibodies plc (AIM:FAB)

Fusion Antibodies Financials Overview

Financials in millions GBP. Fiscal year is April - March.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Revenue Revenue Growth	1.6	1.97	1.14	2.9	4.8	4.17
Revenue Growth	-18.78%	72.97%	-60.84%	-39.55%	15.22%	6.93%
Gross Profit Gross Profit Growth	0.35	0.43	-0.05	0.57	2.47	2.02
Operating Income Operating Income Growth	-1.53	-1.78	-2.29	-2.86	-1.33	-1.25
Net Income Net Income Growth	-1.47	-1.71	-2.23	-2.6	-1.2	-2.9
Earnings Per Share EPS Growth	-0.01	-0.02	-0.04	-0.10	-0.05	-0.11
EPS Growth	-	-	-	-	-	-

Revenue by Geography

Chart

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
United Kingdom United Kingdom Growth	0.57	0.2	0.62	0.72	0.71
Rest of Europe Rest of Europe Growth	0.1	0.1	0.41	1.39	1.13
North America and Rest Of World North America and Rest Of World Growth	1.3	0.85	1.87	-	-
Total Total Growth	1.97	1.14	2.9	4.8	4.17

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Investments Cash & Investments Growth	0.25	0.36	1.2	0.2	2.05	2.69
Total Debt Total Debt Growth	0.39	0.02	0.04	0.08	0.07	0.23
Net Cash (Debt) Net Cash Growth	-0.14	0.34	1.16	0.12	1.98	2.46
Net Cash Growth	-	-70.67%	863.33%	-93.94%	-19.38%	112.27%
Net Cash Per Share Net Cash Per Share Growth	-0.00	0.00	0.02	0.00	0.08	0.10

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Operating Cash Flow Operating Cash Flow Growth	-1.18	-1.36	-1.77	-1.75	-0.33	-1.14
Capital Expenditures CapEx Growth	-0.07	-0.01	-0	-0.11	-0.26	-0.37
Free Cash Flow Free Cash Flow Growth	-1.25	-1.37	-1.77	-1.87	-0.59	-1.5
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Gross Margin	22.06%	21.88%	-3.96%	19.79%	51.39%	48.60%
Operating Margin	-95.55%	-90.53%	-201.41%	-98.52%	-27.61%	-29.99%
Pretax Margin	-96.05%	-90.43%	-201.50%	-98.55%	-27.78%	-30.35%
Profit Margin	-91.92%	-87.18%	-195.95%	-89.49%	-25.01%	-69.60%
FCF Margin	-78.26%	-69.92%	-155.90%	-64.39%	-12.25%	-36.04%

Valuation

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul 26, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
PS Ratio	8.42	3.00	1.83	3.45	3.24	9.60

Data Sources: Fiscal.ai and S&P Global Market Intelligence Last updated: Nov 24, 2025

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every six months for this company. Revenue segment data is provided by S&P Global Market Intelligence.

Update frequency:

Semi-annually

Last checked:

Jul 24, 2026

Data Sources Report a data error